Disposable Iomed Patch For Drug Delivery

Disposable iontophoresis patches for transdermal drug delivery. Engineered with Ag/AgCl buffering and proprietary 3D layer architectures to bypass legacy patent restrictions.

This iontophoresis patch is a consumable transdermal interface that utilizes electromotive force to drive ionized aqueous solutions (such as corticosteroids or local anesthetics) across the stratum corneum. Designed to be compatible with standard dose controllers, the substrate operates on the principle of electrical repulsion. The primary engineering focus of this disposable hardware is managing the extreme pH shifts caused by water electrolysis during continuous DC output, while utilizing an alternative physical layer stack to provide B2B distributors a secure path around existing OEM patent architectures.

• Electrochemical pH Buffering 

  Applying a continuous direct current (DC) to human tissue rapidly electrolyzes water, accumulating hydrogen (H+) ions at the anode and hydroxyl (OH-) ions at the cathode. This causes severe chemical burns if unmitigated. Standard carbon electrodes cannot neutralize this reaction. This substrate deploys a sacrificial Silver/Silver Chloride (Ag/AgCl) trace network. During the 40 to 80 mA-min cycle, the Ag/AgCl elements chemically react with the generated ions, neutralizing the fluid boundary layer and stabilizing the pH near physiological levels. 

   

• Structural IP Navigation 

  Distributing drug delivery patches presents a high risk of IP infringement due to heavily protected reservoir and electrode stacking methods. Instead of using a monolithic sponge or top-down fluid injection ports common in patented designs, this pad architecture shifts the fluid vector. Medication is wicked horizontally across a specific gradient mesh before contacting the conductive base. This alternative physical layout effectively bypasses existing patent claims while maintaining identical current distribution properties. 

   

• Capillary Fluid Containment 

  If the injected medication overflows the reservoir, it breaches the adhesive border. A liquid bridge between the active pole and the dispersive pole immediately short-circuits the controller. The internal pad utilizes a highly absorbent, non-woven fiber blend bordered by an aggressive, closed-cell PE foam adhesive dam. The fibers trap up to 2.5cc of liquid within a tight radius, preventing capillary run-off and locking the electrical vector strictly downward into the target tissue.

• Barrier Pouching : The presence of reactive Ag/AgCl traces requires strict atmospheric control. The pads are vacuum-sealed in heavy-duty aluminum-foil pouches to prevent premature oxidation of the silver elements before clinical deployment. 

• Logistics Routing : The precision rotary die-cutting and silver trace screen-printing are performed in our China facilities. Final reservoir lamination and clinical pouch sealing execute at our Vietnam hub to secure supply chain continuity and optimize global trade tariffs.

• Systems : Assembly lines operate within audited ISO 13485:2016 frameworks, ensuring track-and-trace batch records for all raw materials. 

• Biocompatibility : The external skin-contact adhesives and internal wicking matrices are validated against ISO 10993-5 (Cytotoxicity) limits.

B2B procurement teams and digital therapeutics developers can request 3D exploded layer views and physical prototypes of our alternative delivery architectures. 

👉 [Request Iontophoresis Patch Prototypes]

Hot Tags: disposable iomed patch for drug delivery, China disposable iomed patch for drug delivery manufacturers, suppliers, factory, Iontophoresis Patches, dexamethasone for iontophoresis patch, iontophoresis cortisone patch, iomed patch, Iontophoresis Pad, ionto pads